Event-Free Survival (EFS), compared to Disease-Free Survival (DFS), adds a surgical intervention criterion and is often used to evaluate neoadjuvant therapy pre-surgery, or radiotherapy.

Alvotech along with Kashiv Biosciences LLC have publicized their exclusive licensing accord for AVT23 (also called ADL018).

Disease Control Rate refers to the proportion of patients who, according to internationally recognized criteria for alleviating evaluation, achieve tumor relief (PR+CR) and stable disease (SD) after treatment and can maintain for the minimum duration requirement.

This article summarized the latest R&D progress of choline alfoscerate, the Mechanism of Action for choline alfoscerate, and the drug target R&D trends for choline alfoscerate.

PFS is a tumor measurement-based endpoint that primarily evaluates the anti-tumor activity of a drug and, to a certain extent, considers the drug's safety and patient survival (accidental death).

ALX Oncology Holdings Inc. announced encouraging initial results from Phase 2 of its ASPEN-06 trial. The trial evaluates the use of its CD47 blocker, evorpacept, with trastuzumab, CYRAMZA®, and paclitaxel in treating HER2-positive gastric/gastroesophageal junction cancer patients.

ORR is an index directly measuring the anti-tumor activity of a drug and is the most common endpoint based on tumor measurements, evaluated in single-arm trials.

This article summarized the latest R&D progress of cefroxadine, the Mechanism of Action for cefroxadine, and the drug target R&D trends for cefroxadine.

Overall Survival (OS) is the only endpoint solely based on survival events, fairly objective, and precisely measurable.

Boehringer Ingelheim revealed that their interchangeable* biosimilar to Humira®, known as Adalimumab-adbm injection, is now available at a low wholesale acquisition cost.

This article summarized the latest R&D progress of diclofenac diethylamine, the Mechanism of Action for diclofenac diethylamine, and the drug target R&D trends for diclofenac diethylamine.

Caliway Biopharmaceuticals announced successful primary and secondary endpoints of the phase 2 stage 2 trial for CBL-0202, outperforming placebo in ITT and PP groups.